STERO Biotechs is a clinical-stage company that researches and develops novel and improved treatment solutions designed to benefit patients by reducing the side effects of and need for steroid therapy. STERO uses cannabidiol (CBD), a non-psychotropic component of cannabis sativa, which has been shown to possess potent immunomodulatory and anti-inflammatory properties in a variety of indications. The company has commenced several clinical trials, including phase 2a clinical trials for steroid dependent Crohns disease (IBD) in Q1 2020 and for chronic urticaria (hives) in Q3 2020. In addition, STEROs phase 1/2 clinical trial treating patients with severe COVID-19 started in Q1 2021. Additional clinical trials for more indications are in the pipeline for 2021. STERO Biotechs was established in partnership with Mor Research Applications, the technology transfer unit of CLALIT Health Services.